Sale Of Ayurvedic Medicine For Joint Pain Put On Hold

Jammu: In the wake of a complaint received by the office of Drugs and Food Control Organization of J&K regarding an ayurvedic medicine, its sale has been put on hold in the UT till the verification of components used in it.

As per a letter by the office of Deputy Controller, Drugs and Food Control Organization, the available stock of ‘Batnashak Batika’ used for pain in joints has been put on hold till the report of analysis of samples is received.

The drug control authorities took action and lifted the samples of the medicine after social activist Sukesh Khajuria observed that the effect of the ayurvedic medicine was instant, which is contrary to the conventional understanding that these herbal medicines facilitate gradual healing and recovery.

“Pursuant to the communication by Sukesh Khajuria, where he requested for testing of ayurvedic propriety medicine ‘Batnashak Batika’. In this context a team of Drug Control Officers was constituted to investigate the matter,” the letter stated.

The team lifted the samples for analysis with respect to presence of steroids, as alleged by Khajuria. The samples were forwarded to the Indian Institute of Integrative Medicine (IIIM).

Khajuria said the ayurvedic medicine is increasingly being utilised for treatment of joint pains, particularly in patients who suffered from Chikungunya disease.

“Given the remarkable and expeditious healing attributed to this ayurvedic medicine, I harbour reservations regarding its composition,” Khajuria said.

Khajuria, in a letter to the drug controller, urged that the quality of drugs is beyond the understanding of common man. “It’s the responsibility of the department to ensure the availability of quality drugs to the public and the market is free from counterfeit, spurious and substandard drugs” he stated.

The social activist also shot off a letter to the Union Minister and other central and union territory officials pointing towards the dangers of sale of such drugs and medicines seeking chemical examinations of these medicines at the earliest.

Related Posts

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Mumbai/Pune: In a major regulatory enforcement action aimed at safeguarding public health, the Maharashtra Food and Drug Administration (FDA) has permanently cancelled the Ayurvedic drug manufacturing licence of Pune-based M/s Inducare Pharma…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care